SCHEMBL27174339

SCHEMBL27174339

Fc1cccnc1-c1ccc(CCl)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 1/20 0.41
▸ GABRG2 P18507 7/20 0.38
▸ GABRB3 P28472 7/20 0.38
▸ GABRA5 P31644 7/20 0.38
▸ GABRA3 P34903 7/20 0.38
▸ GABRA1 P14867 6/20 0.38
▸ SLC2A1 P11166 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ MAPK14 Q16539 1/20 0.36
▸ AKT1 P31749 1/20 0.36
▸ ADRB2 P07550 1/20 0.35
▸ PDE4A P27815 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ HPGD P15428 1/20 0.33
▸ TGFBR1 P36897 1/20 0.33
▸ SIGMAR1 Q99720 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31521744 0.82 MKNK1 (0.47) TRPV1GABRG2GABRB3GABRA5GABRA3
SCHEMBL24793478 0.82 ADRB2 (0.56) TRPV1GABRG2GABRB3GABRA5GABRA3
SCHEMBL27174522 0.82 MKNK1 (0.47) TRPV1GABRG2GABRB3GABRA5GABRA3
SCHEMBL30211282 0.79 SLC2A1 (0.48) TRPV1GABRG2GABRB3GABRA5GABRA3
SCHEMBL411041 0.79 SLC2A1 (0.48) TRPV1GABRG2GABRB3GABRA5GABRA3
SCHEMBL30007391 0.79 MAPK14 (0.53) TRPV1GABRG2GABRB3GABRA5GABRA3
SCHEMBL30211300 0.79 MAPK14 (0.53) TRPV1GABRG2GABRB3GABRA5GABRA3
SCHEMBL27174505 0.79 CYP2A6 (0.51) TRPV1AKT1
SCHEMBL2639667 0.77 FEN1 (0.43) TRPV1GABRG2GABRB3GABRA5GABRA3
SCHEMBL29604199 0.77 FEN1 (0.43) TRPV1GABRG2GABRB3GABRA5GABRA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4547336-A1 USP1 INHIBITORS AND USES THEREOF Zentaur Therapeutics USA Inc. (US) 2025-05-07 — — EP disclosed
CN-119836421-A USP1 inhibitors and uses thereof 森韬医药美国公司 2025-04-15 — — CN disclosed
US-20240092779-A1 USP1 INHIBITORS AND USES THEREOF ZENTAUR THERAPEUTICS USA INC. 2024-03-21 — — US disclosed
WO-2024006879-A1 USP1 INHIBITORS AND USES THEREOF ZENTAUR THERAPEUTICS USA INC. (US) 2024-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092779-A1 USP1 INHIBITORS AND USES THEREOF USP1, USP28, USP2 TRPV1 4823/4885GABRG2 3026/4885GABRB3 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback